Optimizing Sequence of PD-L1 Immune-Checkpoint Inhibitors and Radiation Therapy in Bladder Cancer
Authors:
Open Access
- 6 August 2020
- journal article
- research article
- Published by SAGE Publications in Bladder Cancer
- Vol. 6 (3) , 295-302
Abstract
BACKGROUND: New bladder preserving strategies are needed for muscle invasive bladder cancer (MIBC). Combined therapy of immune-checkpoint inhibitors and radiation was shown to have synergistic antitumoral effects in preclinical studies. OBJECTIVES: We aim to evaluate whether the sequence of administration of this combined therapy impacts antitumoral response. METHODS: We developed an in-vivo syngeneic MIBC mouse model where murine bladder cancer cells (MB49) were injected subcutaneously in the right flank of C57BL/6 mice. Mice were then randomized to the following treatments: control, anti-programmed cell death ligand 1 (PD-L1) alone, radiation alone (XRT) consisting of 6.25 Gy x2 fractions, concurrent anti-PD-L1 with XRT, neoadjuvant anti-PD-L1 followed by XRT, or XRT followed by adjuvant anti-PD-L1 therapy. Tumor growth, survival, and rate of response were analyzed. RESULTS: Total of 60 mice were randomized. One-way analysis of variance showed statistically significant difference in tumor growth rate across the treatment arms ( p = 0.029). Importantly, timing of immunotherapy (neoadjuvant, concurrent, or adjuvant) did not alter either tumor growth or survival ( p > 0.05). The rate of response was also similar in each combination arm ( p > 0.05). CONCLUSION: Combining anti-PD-L1 immunotherapy and radiation therapy offers optimal antitumoral responses. Timing of immunotherapy (neoadjuvant, concurrent, or adjuvant) does not appear to affect outcomes. Whether the toxicity profile differs across various sequential deliveries of combination therapy requires further evaluation.Keywords
This publication has 33 references indexed in Scilit:
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in miceJournal of Clinical Investigation, 2014
- Radiation and immunotherapy: a synergistic combinationJournal of Clinical Investigation, 2013
- Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysisCancer Epidemiology, 2013
- Epidemiology and Risk Factors of Urothelial Bladder CancerEuropean Urology, 2013
- Combining Radiotherapy and Cancer Immunotherapy: A Paradigm ShiftJNCI: Journal of the National Cancer Institute, 2013
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 AntibodyClinical Cancer Research, 2009
- Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Clinical radiobiology of stage T2-T3 bladder cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004